Abstract:This manuscript for the first time found that Zoledronic acid (ZOL) has a certain immunomodulatory effect that exhibits anti‐inflammatory properties at lower concentrations, which can weaken lipopolysaccharide (LPS)‐induced osteoclasts differentiation and function through inhibiting NLRP3‐autophagy pathway. These observations suggested that NLRP3/autophagy pathway have a great influence in the inhibition of osteoclastogenesis by ZOL in inflammatory microenvironment, and providing a new idea and a valuable reference for assessing the pharmacological impact of nitrogen‐containing bisphosphonates on bone tissue during inflammation and the application of this drug in the regulation of bone resorption in inflammatory bone diseases like periodontitis or peri‐implantitis. Introduction Inflammatory factors leading to bone loss significantly increase the risk of tooth loosening or implantation failure. Zoledronic acid (ZOL) is a widely used medication for effectively inhibiting excessive bone destruction, but its effect on alleviating inflammatory bone loss remains to be elucidated. In this study, we investigated whether ZOL alleviates inflammatory bone resorption through immunomodulatory effect. Methods The viability of the cells was evaluated by Cell Counting Kit 8 (CCK8) assay. Osteoclast (OC) differentiation and function were determined by tartrate‐resistant acid phosphatase (TRAP) staining and bone resorption pits assays, respectively. Autophagosomes and actin ring structures of OC were observed using transmission electron microscopy (TEM) and F‐actin ring staining, respectively. The microstructure in mice maxillary alveolar bone model was observed by micro computed tomography (Miro‐CT). Reverse transcription‐quantitative PCR (RT‐qPCR) to detect the mRNA expression of osteoclast‐related genes and Western blot (WB) analysis to evaluate the protein expression levels of autophagy‐related proteins and the NOD‐like receptor family pyrin domain‐containing protein 3 (NLRP3)‐related proteins in pre‐OCs. Results The findings indicated that ZOL hindered lipopolysaccharide (LPS)‐mediated OC differentiation, formation, bone resorption activity and autophagosome levels. Furthermore, ZOL diminished the expression of genes associated with OC. And the expression of proteins ATG7, LC3II, Beclin1, NLRP3‐related proteins and tumor necrosis factor‐α (TNF‐α) protein were markedly decreased while P62 was increased, especially in the 1 μM ZOL group or MCC950 + ZOL group. Conclusions ZOL has a certain immunomodulatory effect that exhibits anti‐inflammatory properties at lower concentrations, which can weaken LPS‐induced OCs differentiation and function, and NLRP3‐mediated autophagy pathway may participate in this process.

Lycorine Attenuates Autophagy in Osteoclasts via an Axis of mROS/TRPML1/TFEB to Reduce LPS-Induced Bone Loss

Lycorine Protects Cartilage Through Suppressing the Expression of Matrix Metalloprotenases in Rat Chondrocytes and in a Mouse Osteoarthritis Model.

Lycorine Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents Ovariectomy-Induced Osteoporosis and Titanium Particle-Induced Osteolysis in Vivo

Autophagy Negative-Regulating Wnt Signaling Enhanced Inflammatory Osteoclastogenesis from Pre-OCs in Vitro

Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge

Lycorine Regulate LXRα-Lipid Raft-TlLR4/NF-κB Signal Network to Inhibit Inflammation in Lung of Mice

Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway

Morin Disrupts Cytoskeleton Reorganization in Osteoclasts through an ROS/SHP1/c-Src Axis and Grants Protection from LPS-Induced Bone Loss

Low-intensity Pulsed Ultrasound Inhibits RANKL-induced Osteoclast Formation Via Modulating ERK-c-Fos-NFATc1 Signaling Cascades.

Lycorine attenuates lipopolysaccharide-induced acute lung injury through the HMGB1/TLRs/NF-κB pathway

Carnosol Attenuates RANKL-induced Osteoclastogenesis in Vitro and LPS-induced Bone Loss.

Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo

Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.

Zoledronic Acid Inhibits Lipopolysaccharide‐Induced Osteoclastogenesis by Suppressing Macrophage NLRP3‐Mediated Autophagy Pathway

Lycopus lucidus Turcz Inhibits the Osteoclastogenesis in RAW 264.7 Cells and Bone Loss in Ovariectomized Rat Model

Astragalus polysaccharide attenuates LPS-related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway

Inhibition of JNK and Activation of the AMPK-Nrf2 Axis by Corosolic Acid Suppress Osteolysis and Oxidative Stress

Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition

Alpinetin ameliorates bone loss in LPS-induced inflammation osteolysis via ROS mediated P38/PI3K signaling pathway

Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway

Luteoloside Prevents Lipopolysaccharide-Induced Osteolysis and Suppresses RANKL-Induced Osteoclastogenesis Through Attenuating RANKL Signaling Cascades.